For the past week, we have fielded several phone calls and emails asking us about the status of our clinical data for our Phase IIb study in treating Adrenomyeloneuropathy (AMN). While we are working diligently to get this information compiled, analyzed, and published as quickly as possible, it has taken a little longer than expected […]
|
||||
|
|
||||
